[go: up one dir, main page]

WO1996009395A3 - Drug for the prevention and treatment of auto-immune and viral diseases, and diagnostic agents for detecting said diseases - Google Patents

Drug for the prevention and treatment of auto-immune and viral diseases, and diagnostic agents for detecting said diseases Download PDF

Info

Publication number
WO1996009395A3
WO1996009395A3 PCT/EP1995/003726 EP9503726W WO9609395A3 WO 1996009395 A3 WO1996009395 A3 WO 1996009395A3 EP 9503726 W EP9503726 W EP 9503726W WO 9609395 A3 WO9609395 A3 WO 9609395A3
Authority
WO
WIPO (PCT)
Prior art keywords
ipp
immune
auto
diseases
humans
Prior art date
Application number
PCT/EP1995/003726
Other languages
German (de)
French (fr)
Other versions
WO1996009395A2 (en
Inventor
Thomas Franz Ferdinand Meyer
Johannes Pohlner
Susanne Christine Beck
Joachim Jose
Uwe Woelk
Dirk R Lorenzen
Karin Brigitte Oetzelberger
Original Assignee
Max Planck Gesellschaft
Thomas Franz Ferdinand Meyer
Johannes Pohlner
Susanne Christine Beck
Joachim Jose
Uwe Woelk
Dirk R Lorenzen
Oetzelfberger Karin Brigitte
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft, Thomas Franz Ferdinand Meyer, Johannes Pohlner, Susanne Christine Beck, Joachim Jose, Uwe Woelk, Dirk R Lorenzen, Oetzelfberger Karin Brigitte filed Critical Max Planck Gesellschaft
Priority to AU36515/95A priority Critical patent/AU3651595A/en
Publication of WO1996009395A2 publication Critical patent/WO1996009395A2/en
Publication of WO1996009395A3 publication Critical patent/WO1996009395A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rehabilitation Therapy (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)

Abstract

The present invention concerne drugs and diagnostic agents as well as diagnostic, therapeutic and preventive methods for treating auto-immune and viral diseases in humans, these diseases being caused by pathogenic bacteria which are, in particular, micro-organisms colonizing human mucus membranes and secreting given exoproteins which display structural similarities to human proteins. Proteins similar to IgA protease which are absorbed particularly well by cells and present as antigens on MHC molecules are of particular significance in this respect. The IgA protease polyprotein (IPP) of pathogenic Neisseriae has a particularly marked homology to human proteins. For example, a given IPP peptide has marked homology to the articular proteins link and aggrekan. It is thus proven, for example, that the IPP is an etiological agent of rheumatoid arthritis (RA). The auto-immune reaction is further encouraged by other properties of the IPP-producing Neisseriae and IPPs. A particularly important property is the ability of the IPP to activate viruses and viral elements. This concerns in particular the activation of proviral retroviruses and endogenic retroviruses in humans. Further auto-immune reactions are induced in humans owing to the activation of viruses and viral elements. The development of acquired immune deficiency syndrome (AIDS) is also explained by the IPP-dependent activation of the HIV provirus. The properties according to the invention of the pathogenic Neisseriae and the IPPs formed thereby give rise to numerous novel diagnostic, therapeutic and preventive processes.
PCT/EP1995/003726 1994-09-21 1995-09-21 Drug for the prevention and treatment of auto-immune and viral diseases, and diagnostic agents for detecting said diseases WO1996009395A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU36515/95A AU3651595A (en) 1994-09-21 1995-09-21 Drug for the prevention and treatment of auto-immune and viral diseases, and diagnostic agents for detecting said diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4433708.6 1994-09-21
DE4433708 1994-09-21

Publications (2)

Publication Number Publication Date
WO1996009395A2 WO1996009395A2 (en) 1996-03-28
WO1996009395A3 true WO1996009395A3 (en) 1996-07-18

Family

ID=6528818

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/003726 WO1996009395A2 (en) 1994-09-21 1995-09-21 Drug for the prevention and treatment of auto-immune and viral diseases, and diagnostic agents for detecting said diseases

Country Status (2)

Country Link
AU (1) AU3651595A (en)
WO (1) WO1996009395A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE512216T1 (en) 2001-04-10 2011-06-15 Agensys Inc NUCLEIC ACID AND THIS CORRESPONDING PROTEIN, CALLED 184P1E2, SUITABLE FOR THE TREATMENT AND DETECTION OF CANCER

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0254090A1 (en) * 1986-07-02 1988-01-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Process for recovering proteins by means of gene technology using gram-negative host cells
WO1990011367A1 (en) * 1989-03-17 1990-10-04 Mogens Kilian IMMUNOGLOBULIN A1 PROTEASES (IgA1 PROTEASES), METHOD OF GENE-TECHNOLOGICALLY PRODUCING THIS TYPE OF ENZYME AND VACCINES CONTAINING THE ENZYMES AND FRAGMENTS THEREOF FOR IMMUNIZING AGAINST BACTERIAL MENINGITIS AND OTHER DISEASES CAUSED BY IgA1 PROTEASE-PRODUCING BACTERIA
WO1991011520A1 (en) * 1990-02-03 1991-08-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. PROCESS FOR ENZYMATICAL CLEAVAGE OF RECOMBINANT PROTEINS BY MEANS OF IgA PROTEASES
EP0495398A1 (en) * 1991-01-11 1992-07-22 Roche Diagnostics GmbH Recombinant IgA-protease
WO1992013871A1 (en) * 1991-01-31 1992-08-20 Washington University Polypeptides and polynucleotides useful for the diagnosis and treatment of pathogenic neisseria
WO1992016643A1 (en) * 1991-03-14 1992-10-01 Imclone Systems Incorporated Recombinant hybrid porin epitopes
WO1994006421A1 (en) * 1992-09-16 1994-03-31 The University Of Tennessee Research Corporation Recombinant multivalent m protein vaccine

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0254090A1 (en) * 1986-07-02 1988-01-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Process for recovering proteins by means of gene technology using gram-negative host cells
WO1990011367A1 (en) * 1989-03-17 1990-10-04 Mogens Kilian IMMUNOGLOBULIN A1 PROTEASES (IgA1 PROTEASES), METHOD OF GENE-TECHNOLOGICALLY PRODUCING THIS TYPE OF ENZYME AND VACCINES CONTAINING THE ENZYMES AND FRAGMENTS THEREOF FOR IMMUNIZING AGAINST BACTERIAL MENINGITIS AND OTHER DISEASES CAUSED BY IgA1 PROTEASE-PRODUCING BACTERIA
WO1991011520A1 (en) * 1990-02-03 1991-08-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. PROCESS FOR ENZYMATICAL CLEAVAGE OF RECOMBINANT PROTEINS BY MEANS OF IgA PROTEASES
EP0495398A1 (en) * 1991-01-11 1992-07-22 Roche Diagnostics GmbH Recombinant IgA-protease
WO1992013871A1 (en) * 1991-01-31 1992-08-20 Washington University Polypeptides and polynucleotides useful for the diagnosis and treatment of pathogenic neisseria
WO1992016643A1 (en) * 1991-03-14 1992-10-01 Imclone Systems Incorporated Recombinant hybrid porin epitopes
WO1994006421A1 (en) * 1992-09-16 1994-03-31 The University Of Tennessee Research Corporation Recombinant multivalent m protein vaccine

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ARZESE ET AL: "COMPARITIVE STUDIES OF THE IGA1 PROTEASE GENES FROM HAEMOPHILUS INFLUENZAE,NEISSERIA GONORRHOEAE,AND PREVOTELLA MELANINOGENICA", CLINICAL INFECTIOUS DISEASES, vol. 20, no. S2, June 1995 (1995-06-01), pages S169 - S171, XP002003047 *
HALTER ET AL: "IGA PROTEASE OF NEISSERIA GONORRHOEAE: ISOLATION AND CHARACTERIZATION OF THE GENE AND ITS EXTRACELLULAR PRODUCT", THE EMBO JOURNAL, vol. 3, no. 7, 1984, pages 1595 - 1601, XP002003042 *
KLAUSER ET AL: "EXTRACELLULAR TRANSPORT OF CHOLERA TOXIN B SUBUNIT USING NEISSERIA IGA PROTEASE BETA-DOMAIN:CONFORMATION- DEPENDENT OUTER MEMBRANE TRANSLOCATION", THE EMBO JOURNAL, vol. 9, no. 6, 1990, pages 1991 - 1999, XP002003041 *
LOMHOLT ET AL: "COMPARITIVE CHARACTERIZATION OF THE IGA GENE ENCODING IGA1 PROTEASE IN NEISSERIA MENINGITIDIS, NEISSERIA GONORRHOEAE AND HAEMOPHILUS INFLUENZAE", MOLECULAR MICROBIOLOGY, vol. 15, no. 3, 1995, pages 495 - 506, XP002003045 *
LOMHOLT ET AL: "SIGNIFICANTLY DIFFERENT DEGREES OF ANTIGENIC HETEROGENEITY AMONG IGA1 PROTEASES SECRETED BY SPECIES OF STREPTOCOCCUS,NEISSERIA AND HAEMOPHILUS", JOURNAL OF CELLULAR BIOCHEMISTRY,SUPPLEMENT 19A, 5 January 1995 (1995-01-05) - 26 January 1995 (1995-01-26), pages 248, XP002003048 *
POHLNER ET AL: "GENE STRUCTURE AND EXTRACELLULAR SECRETION OF NEISSERIA GONORRHOEAE IGA PROTEASE", NATURE, vol. 325, 1987, pages 458 - 462, XP002003040 *
POHLNER ET AL: "SEQUENCE-SPECIFIC CLEAVAGE OF PROTEIN FUSIONS USING A RECOMBINANT NEISSERIA TYPE 2 IGA PROTEASE", BIO/TECHNOLOGY, vol. 10, 1992, pages 799 - 804, XP002003043 *
POHLNER ET AL: "UPTAKE AND NUCLEAR TRANSPORT OF NEISSERIA IGA1 PROTEASE- ASSOCIATED ALPHA-PROTEINS IN HUMAN CELLS", MOLECULAR MICROBIOLOGY, vol. 17, no. 6, 1995, pages 1073 - 1083, XP002003046 *
POULSEN ET AL: "PRIMARY STRUCTURE OF NEISSERIA MENINGITIDIS IGA1 PROTEASES IN RELATION TO CLEAVAGE SPECIFICITY", JOURNAL OF CELLULAR BIOCHEMISTRY,SUPPLEMENT 19A, 5 January 1995 (1995-01-05) - 26 January 1995 (1995-01-26), pages 249, XP002003044 *

Also Published As

Publication number Publication date
WO1996009395A2 (en) 1996-03-28
AU3651595A (en) 1996-04-09

Similar Documents

Publication Publication Date Title
BHAT et al. The galactosyl ceramide/sulfatide receptor binding region of HIV-1 gp120 maps to amino acids 206-275
EP1878742A3 (en) HIV peptides, antigens, vaccine compositions, immunoassay and a method of detecting antibodies induced by HIV
PT1159298E (en) Hiv peptides, antigens and vaccine compositions
ATE264914T1 (en) ANTIVIRAL PROTEINS, DNA CODING THEREOF, AND USE THEREOF
ATE306938T1 (en) USE OF CPG AS AN ADJUVANT FOR HIV VACCINE
MXPA02007413A (en) Novel use.
BG100455A (en) Hiv protease inhibitors
ATE154610T1 (en) SYNTHETIC PEPTIDES DERIVED FROM HIV GP120 ENV PROTEIN AND THEIR APPLICATION
HU901585D0 (en) Method for treatment of viral infections using functional derivatives of icam-1
NO178768C (en) 11-aryl-4-oestrenes and contraceptives containing them
Plourde et al. A randomized, double-blind study of the efficacy of fleroxacin versus trimethoprim-sulfamethoxazole in men with culture-proven chancroid
DE3873327D1 (en) PREPARATION OF MEDICINAL PRODUCTS FOR TREATING IMMUNITY.
KR950010898A (en) Sterilization of Recombinant Human Serum Albumin Pharmaceutical Formulations
Agrawal et al. Generating neutralizing antibodies, Th1 response and MHC non restricted immunogenicity of HIV-I env and gag peptides in liposomes and ISCOMs with in-built adjuvanticity
WO1996009395A3 (en) Drug for the prevention and treatment of auto-immune and viral diseases, and diagnostic agents for detecting said diseases
Yu et al. Protease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sites
Li et al. Maleic anhydride-modified chicken ovalbumin as an effective and inexpensive anti-HIV microbicide candidate for prevention of HIV sexual transmission
AU5061090A (en) Aids therapy
Lachgar et al. Involvement of α-interferon in HIV-1 induced immunosuppression. A potential target for AIDS prophylaxis and treatment
DK0612763T3 (en) Cyclic angiopeptin derivatives, processes for their preparation and pharmaceutical agents containing them
AU5535498A (en) Treatment of HIV positive patients
Essex et al. Antigenic characterization of the human immunodeficiency viruses
Luce The Acquired Immunodeficiency Syndrome: A report on the second international conference on AIDS
EA199700353A1 (en) Compositions and methods for detecting and treating acquired immunodeficiency syndrome
TR199700423A2 (en) Bis-orthosubstituted benzoylguanidines, process for their manufacture, their use as medicine or diagnostic agent, and medicines containing them.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA